Monika Leja, MD
Cardiovascular Disease · Ann Arbor, MINPI 1568673440
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,536 of the $1,861 with a category attached, or 82.5%. Every reported general payment came from a single manufacturer, Janssen Research & Development, LLC. That places this record below the midpoint for cardiovascular disease clinicians in MI, where the typical reported total is $2,775.
Across 10 payments — averaging $186.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$2K
Across 24 payments — averaging $5759.46 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$138K
What the payments were for
- Travel & lodging$1,53683%
- Food & beverage$32517%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 10 | $1,861 |
How this compares
$1,861 in reported general payments places this provider in the 40th percentile of 760 cardiovascular disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 296 | $327,780 |
| JardianceEmpagliflozin | 74 | $97,963 |
| EntrestoSacubitril/Valsartan | 50 | $73,297 |
| XareltoRivaroxaban | 62 | $59,382 |
| Repatha SureclickEvolocumab | 100 | $55,220 |
| BrilintaTicagrelor | 12 | $13,445 |
| Praluent PenAlirocumab | 26 | $13,328 |
| Metoprolol Succinate | 271 | $4,779 |
| Eplerenone | 46 | $4,342 |
| Atorvastatin Calcium | 276 | $3,939 |
| Torsemide | 112 | $2,588 |
| Ezetimibe | 77 | $2,258 |
| Rosuvastatin Calcium | 123 | $2,197 |
| Losartan Potassium | 150 | $1,596 |
| Potassium Chloride | 64 | $1,452 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Ann Arbor
- Marschall RungeAnn Arbor$1.8M
- Vallerie McLaughlinAnn Arbor$947K
- Stanley ChetcutiAnn Arbor$573K
- David BachAnn Arbor$390K
- Bertram PittAnn Arbor$298K
- Victor MolesAnn Arbor$120K
- Salim HayekAnn Arbor$92K
- Ashwini KerkarAnn Arbor$84K
- Priya MehtaAnn Arbor$70K
- Raymond YeowAnn Arbor$61K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.